Research analysts at HC Wainwright hoisted their target price on shares of OncoSec Medical (NASDAQ:ONCS) from $1.50 to $2.00 in a report released on Friday, StockRatingsNetwork.com reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 265.63% from the stock’s previous close.

Separately, analysts at Maxim Group initiated coverage on shares of OncoSec Medical in a research note to investors on Tuesday, October 15th. They set a “buy” rating and a $3.00 price target on the stock.

OncoSec Medical Incorporated is an emerging drug-medical device company. The Company focused on designing, developing and commercializing medical approaches for the treatment of solid cancers.